What Should Clinicians Tell Patients about Placebo and Nocebo Effects? Practical Considerations Based on Expert Consensus
AuthorEvers, Andrea W M
Jensen, Karin B
Atlas, Lauren Y
Beedie, Chris J
Crum, Alia J
Finniss, Damien G
Geers, Andrew L
Meeuwis, Stefanie H
Petrie, Keith J
Wager, Tor D
Kelley, John M
JournalPsychotherapy and Psychosomatics
PublisherS. Karger AG
MetadataShow full item record
AbstractIntroduction: Clinical and laboratory studies demonstrate that placebo and nocebo effects influence various symptoms and conditions after the administration of both inert and active treatments. Objective: There is an increasing need for up-to-date recommendations on how to inform patients about placebo and nocebo effects in clinical practice and train clinicians how to disclose this information. Methods: Based on previous clinical recommendations concerning placebo and nocebo effects, a 3-step, invitation-only Delphi study was conducted among an interdisciplinary group of internationally recognized experts. The study consisted of open- and closed-ended survey questions followed by a final expert meeting. The surveys were subdivided into 3 parts: (1) informing patients about placebo effects, (2) informing patients about nocebo effects, and (3) training clinicians how to communicate this information to the patients. Results: There was consensus that communicating general information about placebo and nocebo effects to patients (e.g., explaining their role in treatment) could be beneficial, but that such information needs to be adjusted to match the specific clinical context (e.g., condition and treatment). Experts also agreed that training clinicians to communicate about placebo and nocebo effects should be a regular and integrated part of medical education that makes use of multiple formats, including face-to-face and online modalities. Conclusions: The current 3-step Delphi study provides consensus-based recommendations and practical considerations for disclosures about placebo and nocebo effects in clinical practice. Future research is needed on how to optimally tailor information to specific clinical conditions and patients' needs, and on developing standardized disclosure training modules for clinicians.
Rights/Terms© 2020 The Author(s) Published by S. Karger AG, Basel.
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/14018
- Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus.
- Authors: Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, Büchel C, Carvalho C, Colagiuri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klinger R, Kelley JM
- Issue date: 2018
- European Headache Federation recommendations for placebo and nocebo terminology.
- Authors: Mitsikostas DD, Blease C, Carlino E, Colloca L, Geers AL, Howick J, Evers AWM, Flaten MA, Kelley JM, Kirsch I, Klinger R, MaassenVanDenBrink A, Moerman DE, Sfikakis PP, Vase L, Wager TD, Benedetti F, European Headache Federation.
- Issue date: 2020 Sep 25
- Can insights from placebo and nocebo mechanisms studies improve the randomized controlled trial?
- Authors: Vase L
- Issue date: 2020 Jul 28
- "Consensus on Placebo and Nocebo Effects Connects Science with Practice:" Reply to "Questioning the Consensus on Placebo and Nocebo Effects".
- Authors: Evers AWM, Colloca L, Blease C, Gaab J, Jensen KB, Atlas LY, Beedie CJ, Benedetti F, Bingel U, Büchel C, Bussemaker J, Colagiuri B, Crum AJ, Finniss DG, Geers AL, Howick J, Klinger R, Meeuwis SH, Meissner K, Napadow V, Petrie KJ, Rief W, Smeets I, Wager TD, Wanigasekera V, Vase L, Kelley JM, Kirsch I, on behalf of the Consortium of Placebo Experts.
- Issue date: 2021
- [Placebo and nocebo effects on itch : Methodological and clinical implications].
- Authors: Tekampe J, Peerdeman KJ, Bartels DJP, van Laarhoven AIM, Evers AWM
- Issue date: 2018 Aug